Human pathological basis of blood vessels and stromal tissue for nanotechnology

Advanced Drug Delivery Reviews

Volumn 74, Issue , 2014, Pages 19-27

  Nishihara, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood vessels; Histopathology; Myofibroblasts; Pericytes; Personalized nanomedicine; Stromal tissue; Vascular structure

Indexed keywords

BLOOD VESSELS; DRUG DELIVERY; ENDOTHELIAL CELLS; FIBROBLASTS; MEDICAL NANOTECHNOLOGY; NANOTECHNOLOGY; TISSUE;

HISTOPATHOLOGY; MYOFIBROBLASTS; PERICYTES; PERSONALIZED NANOMEDICINE; VASCULAR STRUCTURES;

TISSUE; BLOOD VESSELS;

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; NANOCARRIER; ALPHA SMOOTH MUSCLE ACTIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

BLOOD VESSEL; BREAST CANCER; COLON ADENOCARCINOMA; DRUG RESPONSE; ENDOTHELIUM CELL; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; INFECTION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MYOFIBROBLAST; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PARTICLE SIZE; PERICYTE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; STROMA; TUMOR VASCULARIZATION; ARTERIOLE; BLOOD VESSEL TONE; DRUG DELIVERY SYSTEM; INFLAMMATION; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NANOPHARMACEUTICS; PROTEIN EXPRESSION; TISSUE STRUCTURE; TUMOR ASSOCIATED LEUKOCYTE; ANATOMY AND HISTOLOGY; ANIMAL; PATHOLOGY; VASCULARIZATION;

ANIMALS; BLOOD VESSELS; ENDOTHELIAL CELLS; HUMANS; MYOFIBROBLASTS; NANOTECHNOLOGY; NEOPLASMS;

EID: 84906054311     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.01.005     Document Type: Review

References (69)

1. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
2. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011, 63:131-135.
3. Daruwalla J., Greish K., Malcontenti-Wilson C., Muralidharan V., Iyer A., Maeda H., Christophi C. Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases. J. Vasc. Res. 2009, 46:218-228.
4. Maeda H., Fang J., Inutsuka T., Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 2003, 3:319-328.
5. Skinner S.A., Tutton P.J., O'Brien P.E. Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 1990, 50:2411-2417.
6. Kano M.R., Komuta Y., Iwata C., Oka M., Shirai Y.T., Morishita Y., Ouchi Y., Kataoka K., Miyazono K. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2009, 100:173-180.
7. Li H., Fan X., Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell. Biochem. 2007, 101:805-815.
8. Armulik A., Genove G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011, 21:193-215.
9. Cotran R.S. Pathologic Basis of Disease 1999, Saunders. 6th ed.
10. Bazzoni G., Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol. Rev. 2004, 84:869-901.
11. Van Itallie C.M., Anderson J.M. The molecular physiology of tight junction pores. Physiology (Bethesda) 2004, 19:331-338.
12. Sawada N., Murata M., Kikuchi K., Osanai M., Tobioka H., Kojima T., Chiba H. Tight junctions and human diseases. Med. Electron Microsc. 2003, 36:147-156.
13. Sohl G., Willecke K. Gap junctions and the connexin protein family. Cardiovasc. Res. 2004, 62:228-232.
14. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
15. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
16. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 2001, 46:169-185.
17. Fang J., Sawa T., Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv. Exp. Med. Biol. 2003, 519:29-49.
18. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on -effect. Eur. J. Pharm. Biopharm. 2009, 71:409-419.
19. Zhang L., Nishihara H., Kano M.R. Pericyte-coverage of human tumor vasculature and nanoparticle permeability. Biol. Pharm. Bull. 2012, 35:761-766.
20. Kano M.R., Bae Y., Iwata C., Morishita Y., Yashiro M., Oka M., Fujii T., Komuro A., Kiyono K., Kaminishi M., Hirakawa K., Ouchi Y., Nishiyama N., Kataoka K., Miyazono K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3460-3465.
21. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., Terada Y., Kano M.R., Miyazono K., Uesaka M., Nishiyama N., Kataoka K. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6:815-823.
22. Rojiani A.M., Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J. Neurosurg. 1996, 85:1078-1084.
23. Akslen L.A., Straume O., Geisler S., Sorlie T., Chi J.T., Aas T., Borresen-Dale A.L., Lonning P.E. Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. Br. J. Cancer 2011, 105:9-12.
24. Straume O., Chappuis P.O., Salvesen H.B., Halvorsen O.J., Haukaas S.A., Goffin J.R., Begin L.R., Foulkes W.D., Akslen L.A. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res. 2002, 62:6808-6811.
25. Tanaka F., Oyanagi H., Takenaka K., Ishikawa S., Yanagihara K., Miyahara R., Kawano Y., Li M., Otake Y., Wada H. Glomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer. Cancer Res. 2003, 63:6791-6794.
26. Foulkes W.D., Brunet J.S., Stefansson I.M., Straume O., Chappuis P.O., Begin L.R., Hamel N., Goffin J.R., Wong N., Trudel M., Kapusta L., Porter P., Akslen L.A. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004, 64:830-835.
27. Dulmovits B.M., Herman I.M. Microvascular remodeling and wound healing: a role for pericytes. Int. J. Biochem. Cell Biol. 2012, 44:1800-1812.
28. Gabbiani G., Ryan G.B., Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971, 27:549-550.
29. Mills S.E. Histology for Pathologists 2007, Lippincott Williams & Wilkins. 3rd ed.
30. Hinz B., Gabbiani G. Cell-matrix and cell-cell contacts of myofibroblasts: role in connective tissue remodeling. Thromb. Haemost. 2003, 90:993-1002.
31. Boya J., Carbonell A.L., Martinez A. Myofibroblasts in human palatal mucosa. Acta Anat. (Basel) 1988, 131:161-165.
32. Guldner F.H., Wolff J.R., Keyserlingk D.G. Fibroblasts as a part of the contractile system in duodenal villi of rat. Z. Zellforsch. Mikrosk. Anat. 1972, 135:349-360.
33. Kaye G.I., Lane N., Pascal R.R. Colonic pericryptal fibroblast sheath: replication, migration, and cytodifferentiation of a mesenchymal cell system in adult tissue. II. Fine structural aspects of normal rabbit and human colon. Gastroenterology 1968, 54:852-865.
34. Sappino A.P., Dietrich P.Y., Skalli O., Widgren S., Gabbiani G. Colonic pericryptal fibroblasts. Differentiation pattern in embryogenesis and phenotypic modulation in epithelial proliferative lesions. Virchows Arch A Pathol Anat Histopathol 1989, 415:551-557.
35. Kapanci Y., Assimacopoulos A., Irle C., Zwahlen A., Gabbiani G. "Contractile interstitial cells" in pulmonary alveolar septa: a possible regulator of ventilation-perfusion ratio? Ultrastructural, immunofluorescence, and in vitro studies. J. Cell Biol. 1974, 60:375-392.
36. Charbord P., Lerat H., Newton I., Tamayo E., Gown A.M., Singer J.W., Herve P. The cytoskeleton of stromal cells from human bone marrow cultures resembles that of cultured smooth muscle cells. Exp. Hematol. 1990, 18:276-282.
37. Kondo T., Ishida Y. Molecular pathology of wound healing. Forensic Sci. Int. 2010, 203:93-98.
38. Zhang K., Rekhter M.D., Gordon D., Phan S.H. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am. J. Pathol. 1994, 145:114-125.
39. Gabbiani G., Le Lous M., Bailey A.J., Bazin S., Delaunay A. Collagen and myofibroblasts of granulation tissue. A chemical, ultrastructural and immunologic study. Virchows Arch. B Cell Pathol. 1976, 21:133-145.
40. Rudolph R., Guber S., Suzuki M., Woodward M. The life cycle of the myofibroblast. Surg. Gynecol. Obstet. 1977, 145:389-394.
41. Barsky S.H., Rao C.N., Grotendorst G.R., Liotta L.A. Increased content of Type V Collagen in desmoplasia of human breast carcinoma. Am. J. Pathol. 1982, 108:276-283.
42. Gressner A.M., Bachem M.G. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin. Liver Dis. 1990, 10:30-46.
43. Berndt A., Kosmehl H., Katenkamp D., Tauchmann V. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 1994, 62:55-58.
44. Powell D.W., Pinchuk I.V., Saada J.I., Chen X., Mifflin R.C. Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. 2011, 73:213-237.
45. Varga J.A., Trojanowska M. Fibrosis in systemic sclerosis. Rheum. Dis. Clin. North Am. 2008, 34:115-143. (vii).
46. Psarros C., Lee R., Margaritis M., Antoniades C. Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Maturitas 2012, 73:52-60.
47. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147.
48. Hinz B., Phan S.H., Thannickal V.J., Galli A., Bochaton-Piallat M.L., Gabbiani G. The myofibroblast: one function, multiple origins. Am. J. Pathol. 2007, 170:1807-1816.
49. Polanska U.M., Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013, 228:1651-1657.
50. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5:1640-1646.
51. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
52. Yuzawa S., Kano M.R., Einama T., Nishihara H. PDGFRbeta expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Med. Oncol. 2012, 29:2824-2830.
53. Barker H.E., Cox T.R., Erler J.T. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer 2012, 12:540-552.
54. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
55. Samuel M.S., Lopez J.I., McGhee E.J., Croft D.R., Strachan D., Timpson P., Munro J., Schroder E., Zhou J., Brunton V.G., Barker N., Clevers H., Sansom O.J., Anderson K.I., Weaver V.M., Olson M.F. Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 2011, 19:776-791.
56. Sounni N.E., Noel A. Targeting the tumor microenvironment for cancer therapy. Clin. Chem. 2013, 59:85-93.
57. Bauerle T., Komljenovic D., Merz M., Berger M.R., Goodman S.L., Semmler W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int. J. Cancer 2011, 128:2453-2462.
58. Murray P.J., Wynn T.A. Obstacles and opportunities for understanding macrophage polarization. J. Leukoc. Biol. 2011, 89:557-563.
59. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 1992, 176:287-292.
60. Goerdt S., Orfanos C.E. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 1999, 10:137-142.
61. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
62. Ong S.M., Tan Y.C., Beretta O., Jiang D., Yeap W.H., Tai J.J., Wong W.C., Yang H., Schwarz H., Lim K.H., Koh P.K., Ling K.L., Wong S.C. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur. J. Immunol. 2012, 42:89-100.
63. Dumont P., Berton A., Nagy N., Sandras F., Tinton S., Demetter P., Mascart F., Allaoui A., Decaestecker C., Salmon I. Expression of galectin-3 in the tumor immune response in colon cancer. Lab. Invest. 2008, 88:896-906.
64. Nardin A., Abastado J.P. Macrophages and cancer. Front. Biosci. 2008, 13:3494-3505.
65. Hao N.B., Lu M.H., Fan Y.H., Cao Y.L., Zhang Z.R., Yang S.M. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 2012:948098.
66. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148:135-146.
67. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30:592-599.
68. Gullotti E., Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol. Pharm. 2009, 6:1041-1051.
69. Gupta A.S. Nanomedicine approaches in vascular disease: a review. Nanomedicine 2011, 7:763-779.